Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Nasopharyngeal Carcinoma
Drug:
carboplatin
(
Tubulin polymerization promoter
) +
paclitaxel
(
Tubulin inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Combination Therapy…Cisplatin or carboplatin/docetaxel...or paclitaxel
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.